Brooklyn Investment Group Acquires Shares of 1,635 Exelixis, Inc. (NASDAQ:EXEL)

Brooklyn Investment Group acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,635 shares of the biotechnology company’s stock, valued at approximately $42,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. V Square Quantitative Management LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at approximately $30,000. Park Place Capital Corp purchased a new position in shares of Exelixis during the 2nd quarter valued at approximately $45,000. GAMMA Investing LLC increased its holdings in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Exelixis during the 3rd quarter valued at approximately $61,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at approximately $74,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The trade was a 3.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 279,736 shares of company stock valued at $9,308,410. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 1.5 %

Shares of EXEL opened at $36.46 on Friday. Exelixis, Inc. has a 52-week low of $19.20 and a 52-week high of $36.97. The firm’s fifty day moving average is $30.62 and its two-hundred day moving average is $25.97. The stock has a market cap of $10.41 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 0.90 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. As a group, research analysts anticipate that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on EXEL. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 target price on shares of Exelixis in a report on Wednesday, October 30th. UBS Group initiated coverage on shares of Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price target for the company. Bank of America boosted their price target on shares of Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. Stephens boosted their price target on shares of Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group raised shares of Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.